Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) shares, rose in value on Friday, December 13, with the stock price down by -3.52% to the previous day’s close as strong demand from buyers drove the stock to $53.66.
Actively observing the price movement in the last trading, the stock closed the session at $55.62, falling within a range of $53.36 and $56.53. The value of beta (5-year monthly) was 0.619. Referring to stock’s 52-week performance, its high was $62.53, and the low was $32.64. On the whole, CRNX has fluctuated by -8.93% over the past month.
With the market capitalization of Crinetics Pharmaceuticals Inc currently standing at about $4.98 billion, investors are eagerly awaiting this quarter’s results, scheduled for in January.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 700k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRNX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of CRNX currently trading nearly -5.14% and -5.46% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.96, while the 7-day volatility ratio is showing 5.96% which for the 30-day chart, stands at 4.52%. Furthermore, Crinetics Pharmaceuticals Inc (CRNX)’s beta value is 0.58, and its average true range (ATR) is 2.49.
A comparison of Crinetics Pharmaceuticals Inc (CRNX) with its peers suggests the former has fared considerably weaker in the market. CRNX showed an intraday change of -3.52% in last session, and over the past year, it grew by 55.85%%.
Data on historical trading for Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) indicates that the trading volumes over the past 10 days have averaged 0.56 and over the past 3 months, they’ve averaged 723.64K. According to company’s latest data on outstanding shares, there are 92.74 million shares outstanding.
Nearly 6.31% of Crinetics Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 88.23% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.01 million shares as on 2024-11-29, resulting in a short ratio of 9.53. According to the data, the short interest in Crinetics Pharmaceuticals Inc (CRNX) stood at 660.00 of shares outstanding as of 2024-11-29; the number of short shares registered in 2024-10-31 reached 6.94 million. The stock has risen by 50.82% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRNX stock heading into the next quarter.
